PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

SHISA3 Promoter Methylation Is a Potential Diagnostic and Prognostic Biomarker for Laryngeal Squamous Cell Carcinoma.

Abstract The purpose of this study was to evaluate the contribution of SHISA3 promoter methylation to laryngeal squamous cell carcinoma (LSCC). SHISA3 promoter methylation status and expression were determined using methylation-specific polymerase chain reaction (MSP) and quantitative real-time PCR (qRT-PCR) in 93 paired LSCC and adjacent normal tissues, respectively. Furthermore, the regulatory function of the SHISA3 promoter fragment was analyzed using a luciferase reporter assay. The results reveal that there is a significant increase in SHISA3 methylation in LSCC tissues compared with corresponding nontumor tissues (P = 4.58E - 12). The qRT-PCR results show a significant association between SHISA3 methylation and expression in LSCC (P = 1.67E - 03). In addition, the area under the receiver operating characteristic curve was 0.91. Consequently, a log-rank test and multivariate Cox analysis suggest that SHISA3 promoter hypermethylation is a predictor of poor overall survival for LSCC (log-rank P = 0.024; HR = 2.71; 95% CI = 1.024-7.177; P = 0.047). The results indicate that SHISA3 promoter hypermethylation might increase the risk of LSCC through regulation of gene expression and is a potential diagnostic and prognostic biomarker for LSCC.
PMID
Related Publications

Promoter hypermethylation-induced transcriptional down-regulation of the gene MYCT1 in laryngeal squamous cell carcinoma.

Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.

DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.

Promoter hypermethylation of miR-34a contributes to the risk, progression, metastasis and poor survival of laryngeal squamous cell carcinoma.

SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males.

Authors

Mayor MeshTerms

DNA Methylation

Promoter Regions, Genetic

Keywords
Journal Title biomed research international
Publication Year Start




PMID- 28299336
OWN - NLM
STAT- MEDLINE
DA  - 20170316
DCOM- 20170417
LR  - 20170417
IS  - 2314-6141 (Electronic)
VI  - 2017
DP  - 2017
TI  - SHISA3 Promoter Methylation Is a Potential Diagnostic and Prognostic Biomarker
      for Laryngeal Squamous Cell Carcinoma.
PG  - 9058749
LID - 10.1155/2017/9058749 [doi]
AB  - The purpose of this study was to evaluate the contribution of SHISA3 promoter
      methylation to laryngeal squamous cell carcinoma (LSCC). SHISA3 promoter
      methylation status and expression were determined using methylation-specific
      polymerase chain reaction (MSP) and quantitative real-time PCR (qRT-PCR) in 93
      paired LSCC and adjacent normal tissues, respectively. Furthermore, the
      regulatory function of the SHISA3 promoter fragment was analyzed using a
      luciferase reporter assay. The results reveal that there is a significant
      increase in SHISA3 methylation in LSCC tissues compared with corresponding
      nontumor tissues (P = 4.58E - 12). The qRT-PCR results show a significant
      association between SHISA3 methylation and expression in LSCC (P = 1.67E - 03).
      In addition, the area under the receiver operating characteristic curve was 0.91.
      Consequently, a log-rank test and multivariate Cox analysis suggest that SHISA3
      promoter hypermethylation is a predictor of poor overall survival for LSCC
      (log-rank P = 0.024; HR = 2.71; 95% CI = 1.024-7.177; P = 0.047). The results
      indicate that SHISA3 promoter hypermethylation might increase the risk of LSCC
      through regulation of gene expression and is a potential diagnostic and
      prognostic biomarker for LSCC.
FAU - Shen, Zhisen
AU  - Shen Z
AUID- ORCID: 0000-0001-6660-0488
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China; School of Medicine, Ningbo
      University, Ningbo, Zhejiang 315211, China.
FAU - Zhou, Chongchang
AU  - Zhou C
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China; School of Medicine, Ningbo
      University, Ningbo, Zhejiang 315211, China.
FAU - Li, Jinyun
AU  - Li J
AD  - School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China.
FAU - Ye, Dong
AU  - Ye D
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China.
FAU - Deng, Hongxia
AU  - Deng H
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China.
FAU - Cao, Bin
AU  - Cao B
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China; School of Medicine, Ningbo
      University, Ningbo, Zhejiang 315211, China.
FAU - Hao, Wenjuan
AU  - Hao W
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China; School of Medicine, Ningbo
      University, Ningbo, Zhejiang 315211, China.
FAU - Lin, Lexi
AU  - Lin L
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China; School of Medicine, Ningbo
      University, Ningbo, Zhejiang 315211, China.
FAU - Zhang, Yuna
AU  - Zhang Y
AUID- ORCID: 0000-0002-3417-0484
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital, Ningbo
      University, Ningbo, Zhejiang 315040, China.
LA  - eng
PT  - Journal Article
DEP - 20170216
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Membrane Proteins)
RN  - Carcinoma, squamous cell of head and neck
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Squamous Cell/diagnosis/*genetics/mortality
MH  - *DNA Methylation
MH  - Epigenesis, Genetic
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, Reporter
MH  - Genes, Tumor Suppressor
MH  - HEK293 Cells
MH  - Head and Neck Neoplasms/diagnosis/*genetics/mortality
MH  - Humans
MH  - Laryngeal Neoplasms/diagnosis/*genetics/mortality
MH  - Membrane Proteins/*genetics
MH  - Prognosis
MH  - *Promoter Regions, Genetic
MH  - Proportional Hazards Models
MH  - ROC Curve
MH  - Transcriptional Activation
PMC - PMC5337399
COI - The authors declare that there is no conflict of interests regarding the
      publication of this article.
EDAT- 2017/03/17 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/03/17 06:00
PHST- 2016/09/04 [received]
PHST- 2016/11/03 [revised]
PHST- 2017/01/10 [accepted]
AID - 10.1155/2017/9058749 [doi]
PST - ppublish
SO  - Biomed Res Int. 2017;2017:9058749. doi: 10.1155/2017/9058749. Epub 2017 Feb 16.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>